Institutional Research Collaboration between the Liverpool School of Tropical Medicine and the Centers for Department of Health and Human Services Centers for Disease Control and Prevention

项目总结 这是疾控中心疟疾科与美国疾病控制与预防中心之间的第三份、五年合作协议 利物浦热带医学院。建议的研究策略遵循以下原则 《行动纲领》概述的目标，涉及4个主题：a)与以下方面有关的业务研究 减少疟疾传播，b)或确定新的或改进的儿童干预措施 严重疟疾贫血和孕妇，c)最大限度地提高公共健康影响 通过支持将控制孕期疟疾的全球政策转化为国家 通过信息交流提高政策水平(3.1)，以及d)加强研究能力 在肯尼亚、马拉维和印度尼西亚的海外合作伙伴提供个人级别的博士学位 以及博士后和小组课程(5.1)。减少疟疾传播或 活动是在肯尼亚和肯尼亚之间长期合作的框架下进行的 肯尼亚医学研究所(KEMRI)和疾病控制与预防中心。LSTM将与CDC合作提供 向KEMRI提供技术支持，以建立追踪疟疾所需的信息基础设施 传播强度和实现疟疾控制目标的进展，包括合理的 衰退形势下大规模昆虫学监测系统的发展 媒介密度，增加户外叮咬和对常用媒介的抵抗力 杀虫剂(1.1)，支持发展加强的半自动例行监测 具有可扫描登记册的系统，并进行持续的疟疾指标调查，以真正- 病例负担和感染率的时间监测(4.1)。LSTM将支持CDC 开发概念并为确定安全性的原则验证研究寻求资金， 群众性给药与抗疟药联合应用的可行性和有效性 室内滞留喷洒(2.1)。它将支持伯喹和伯喹的剂量发现研究 伊维菌素，旨在确定辅助疗法，以增强大众药物的影响 行政管理(MDA)(2.2)，并支持对不同干预措施进行经济评估 以及监测方法，作为减少传播活动的一部分(2.3)。高等学府 风险群体包括改善对疟疾病例管理指南的遵守情况的研究 肯尼亚西部的怀孕(1.2)和三项大型多中心试验，包括一项关于 通过出院后疟疾化学预防预防反弹入院和死亡 在肯尼亚患有严重贫血的儿童中(2.4)，关于控制孕期疟疾的两项： STOPMiP-印度尼西亚(2.6)，STOPMIP2在肯尼亚和马拉维(2.5)评估安全性和 双氢青蒿素-哌喹间歇预防治疗的疗效观察

Project summary This is the 3rd, 5-year collaborative agreement between CDC's Malaria Branch and the Liverpool School of Tropical Medicine (LSTM). The proposed research strategy follows the objectives outlined in the FOA and involves 4 themes: a) Operational research (OR) related to malaria transmission reduction, b) OR to identify novel or improved interventions for children with severe malarial anaemia and pregnant women, c) Maximising the public health impact by supporting translation of global policies for the control of malaria in pregnancy to country level policies through information exchange (3.1), and d) Strengthening research capacity of the overseas partners in Kenya, Malawi and Indonesia by provision of individual level PhD and post-doctoral studentships and group courses (5.1). Malaria transmission reduction OR activities take place under the umbrella of the long-term collaboration between the Kenya Medical Research Institute (KEMRI) and CDC in Kenya. LSTM will work with CDC to provide technical support to KEMRI to build the information infrastructure needed to track malaria transmission intensity and progress towards malaria control targets, including the rational development of large-scale entomological monitoring systems in situations with declining vector densities, increased outdoor biting and vector resistance to the commonly used insecticides (1.1), support the development of enhanced semi-automated routine surveillance systems with scannable registers, and conduct continuous malaria indicator surveys for real- time monitoring of the case-burden and infection prevalence (4.1). LSTM will support CDC to develop the concept and seek funding for proof-of-principle studies that determine the safety, feasibility and effectiveness of mass-drug administration with antimalarials when combined with indoor residual spraying (2.1). It will support dose finding studies with primaquine and ivermectin that aim to identify adjunct therapies to enhance the impact of mass drug administration (MDA) (2.2), and support the economic evaluation of different interventions and surveillance methods as part of the transmission reduction activities (2.3). Studies in high risk groups includes research to improve adherence to malaria case-management guidelines in pregnancy in western Kenya (1.2) and three large multi-centre trials including one on the prevention of rebound admissions and deaths with post-discharge malaria chemoprevention in children with severe anaemia in Kenya (2.4) and two on the control of malaria in pregnancy: STOPMiP-Indonesia (2.6), STOPMIP2 in Kenya and Malawi (2.5) evaluating the safety and efficacy of intermittent preventive therapy with dihydroartemisinin-piperaquine.